These pillars are composed of polyacrylamide hydrogel, a material whose stiffness can be adjusted to match the ~5 kPa ...

Eric Green, MD, PhD, Chief Medical Officer of Illumina, was awarded the Distinguished Service Award by board members of The Genome Partnership—the nonprofit organization that has organized the ...

Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.

FDA approval of the first organoid-supported IND application augurs a future in which new approach methodologies supplant animal testing.

The data shows when the protein is removed from neurons or has its signaling activity blocked with drugs, axonal fibers grew more effectively.

Once physical security measures are circumvented, there are no measures in place to protect cells from theft, abuse, or unauthorized use.

In this Point of View column,, CEO of Taconic Biosciences, explores redefining preclinical models for the future of drug development.

From payload optimization to integrated GMP manufacturing, companies aim to elevate oncology ADCs to standard of care.

To model tumor biology, Emulate’s platform introduces stromal contents by tuning the extracellular matrix stiffness and composition, as well as recreating essential gradients. The method captures ...

From a chemistry, manufacturing, and controls (CMC) perspective, ADCs present unique hurdles. “ADCs introduce unique challenges across areas like process and purification development, analytical ...

The growing emphasis on CLD is evident in market projections. The global cell line development market is expected to expand ...

Eli Lilly agrees to acquire sleep disorder drug developer Centessa Pharmaceuticals for approximately $7.8 billion, while ...